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Abstract
Background
Genetic profiling represents the future of neuro-oncology but suffers from inadequate biop-
sies in heterogeneous tumors like Glioblastoma (GBM). Contrast-enhanced MRI (CE-MRI)
targets enhancing core (ENH) but yields adequate tumor in only ~60% of cases. Further,
CE-MRI poorly localizes infiltrative tumor within surrounding non-enhancing parenchyma,
or brain-around-tumor (BAT), despite the importance of characterizing this tumor segment,
which universally recurs. In this study, we use multiple texture analysis and machine learn-
ing (ML) algorithms to analyze multi-parametric MRI, and produce new images indicating
tumor-rich targets in GBM.
Methods
We recruited primary GBM patients undergoing image-guided biopsies and acquired pre-
operative MRI: CE-MRI, Dynamic-Susceptibility-weighted-Contrast-enhanced-MRI, and
Diffusion Tensor Imaging. Following image coregistration and region of interest placement
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at biopsy locations, we compared MRI metrics and regional texture with histologic diagno-
ses of high- vs low-tumor content (80% vs <80% tumor nuclei) for corresponding samples.
In a training set, we used three texture analysis algorithms and three ML methods to identify
MRI-texture features that optimized model accuracy to distinguish tumor content. We con-
firmed model accuracy in a separate validation set.
Results
We collected 82 biopsies from 18 GBMs throughout ENH and BAT. The MRI-based model
achieved 85% cross-validated accuracy to diagnose high- vs low-tumor in the training set
(60 biopsies, 11 patients). The model achieved 81.8% accuracy in the validation set (22
biopsies, 7 patients).
Conclusion
Multi-parametric MRI and texture analysis can help characterize and visualize GBM’s spa-
tial histologic heterogeneity to identify regional tumor-rich biopsy targets.
Introduction
Glioblastoma (GBM) represents one of the most genetically heterogeneous, resistant, and lethal
of all human cancers [1,2]. While median survival remains poor with conventional therapy, the
use of genomic profiling has ushered promising new approaches to drug discovery and treat-
ment optimization [3]. Recent landmark initiatives by the National Cancer Institute (NCI) and
The Cancer Genome Atlas (TCGA) have sought to catalog GBM’s diverse genetic landscape,
giving insight to pathogenesis, prognosis and therapeutic susceptibility. This should help guide
risk stratification for existing protocols and help identify key driver genes as potential thera-
peutic targets in the future [4]. With improving availability and cost, genomic profiling will
play an ever-increasing role in the paradigm of individualized oncology.
Yet, securing tumor-rich biospecimens for genomic profiling remains a significant chal-
lenge. In their initial report, TCGA found that only 35% of submitted biopsy samples contained
adequate tumoral content and/or genetic material [4]. This low yield relates to GBM’s pro-
found histologic heterogeneity and the limitations of contrast-enhanced MRI (CE-MRI)-
guided biopsies to distinguish enhancing tumor from non-tumoral tissue (e.g., reactive gliosis,
microscopic necrosis). CE-MRI also poorly localizes tumor within surrounding non-enhancing
parenchyma, or Brain Around Tumor (BAT), which appears indistinguishable from non-
tumoral vasogenic edema [5]. Finally, recently proposed multisampling approaches, which
help characterize intratumoral heterogeneity, further increase the risk of low tumor content
because biopsy volumes are typically smaller than en bloc resection [6].
Advanced MRI offers an adjunct to conventional imaging and should help delineate tumor-
rich biopsy targets. Image-based features such as tumor cell density on diffusion-weighted
imaging (DWI), white matter infiltration on diffusion tensor imaging (DTI), and microvessel
morphology on perfusion MRI (pMRI) reflect key biophysical characteristics associated with
tumor pathogenesis [5,7–10]. Additionally, textural patterns between spatially encoded voxels
and their surrounding neighbors provide further insight to regional microstructure and histo-
logic identity [11–14]. And while most imaging techniques have been evaluated individually,
the multi-parametric nature of MRI enables co-localization and incorporation of multiple
MRI and Texture Analysis Detect GBM Tumor Extent
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complementary features to optimize diagnostic accuracy [15]. Multiple texture algorithms
offer similar advantages to using multiple MR contrasts—we expect each algorithm to provide
additional information.
Although prior studies suggest benefits from combining imaging techniques, there is cur-
rently no system that integrates the diverse image-based phenotypes and rich textural data of
multi-parametric MRI to quantify tumor content within biopsy targets. To address this need,
we assess the feasibility of using machine learning (ML) to integrate an array of image-based
texture features from pre-operative MRI to predict tumor-rich biopsies from both enhancing
core and non-enhancing BAT in a cohort of GBM patients. Our overarching goal is to develop
non-invasive correlates of histology that can facilitate image-guided biopsy and genomic profil-
ing within the framework of individualized oncology.
The unique contributions of this study are: 1) a new method to produce images of histologic
tumor content within an individual GBM; 2) a new protocol that uses multiple machine learn-
ing and texture algorithms to analyze co-registered multi-parametric MRI; 3) model construc-
tion and cross-validation in a training cohort of patients, followed by validation in a de-novo
group of patients; and, 4) a model with high accuracy predicting histologic tumor content in
the non-enhancing, and traditionally problematic, brain-around-tumor (BAT) zone.
Methods
Patient recruitment
We recruited patients with clinically suspected GBM undergoing preoperative stereotactic MRI
for surgical resection. We confirmed the absence of previous treatment (including steroid
administration) and excluded subjects with an estimated glomerular filtration rate<60 mg/
min/1.72 m2. We obtained approval from the institutional review boards at Barrow Neurologi-
cal Institute (BNI) and Mayo Clinic in Arizona (MCA) and obtained written and informed
consent from each subject prior to enrollment.
Surgical biopsy
Our group used pre-operative conventional MRI, including T1-Weighted contrast-enhanced
(T1+C) and T2-Weighted sequences (T2W), to guide stereotactic biopsies as previously
described [16]. In short, each neurosurgeon collected an average of 5–6 tissue specimens from
each tumor by using stereotactic surgical localization, following the smallest possible diameter
craniotomies to minimize brain shift. Neurosurgeons selected targets separated by at least 1 cm
from both enhancing core (using T1+C) and non-enhancing BAT (using T1+C and/or T2W)
in pseudorandom fashion, typically from different poles of the enhancing lesion periphery
while avoiding any necrotic regions, based on clinical feasibility as per clinical protocol. The
neurosurgeons recorded biopsy locations via screen capture to allow subsequent coregistration
with multiparametric MRI datasets. The neurosurgeon visually validated stereotactic imaging
locations with corresponding intracranial anatomic landmarks, such as vascular structures and
ventricle margins, before recording specimen locations.
Histologic analysis and biopsy sample classification
Tissue specimens (target volume of 125mg) were flash frozen in liquid nitrogen within 1–2
min from collection in the operating suite and stored in -80°C freezer until subsequent process-
ing. Tissue was retrieved from the freezer and embedded frozen in optimal cutting temperature
(OCT) compound. Tissue was cut at 4 um sections in a -20 degree C cryostat (Microm-HM-
550) utilizing microtome blade. Tissue sections were stained with hematoxylin and eosin
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(H&E) for neuropathology review. H&E slides were reviewed blinded to diagnosis by a neuro-
pathologist and assessed for tumor content. Taking into account all visible cells (neurons,
inflammatory cells, reactive glia, tumor cells, etc.), the percent tumor nuclei were estimated.
Based on the TCGA criteria, we used the threshold of at least 80% tumor nuclei content to
define tumor-rich (i.e., high tumor) biopsy samples [4]. Those with less than 80% tumor con-
tent were classified as low tumor samples.
MRI protocol, parametric maps, and image coregistration
Conventional MRI and general acquisition conditions. We performed all imaging on a
3 Tesla system (Sigma HDx; GE-Healthcare, Milwaukee, Wisconsin) within 1 day prior to ste-
reotactic surgery. Conventional MRI included standard pre- and post-contrast T1-Weighted
(T1-C, T1+C, respectively) and pre-contrast T2-Weighted (T2W) sequences. T1W images
were acquired using spoiled gradient recalled-echo inversion-recovery prepped (SPGR-IR
prepped) (TI/TR/TE, 300/6.8/2.8ms; matrix, 320×224; FOV, 26 cm; thickness 2mm). T2W
images were acquired using fast-spin-echo (FSE) (TR/TE, 5133/78ms; matrix 320x192; FOV
26cm; thickness 2mm). T1+C images were acquired after completion of Dynamic Susceptibil-
ity-weighted Contrast-enhanced (DSC) Perfusion MRI (pMRI) following total Gd-DTPA
(gadobenate dimeglumine) dosage of 0.15 mmol/kg as described below [16,17].
Diffusion Tensor (DTI). DTI imaging was performed using Spin-Echo Echo-planar
imaging (EPI) [TR/TE 10000/85.2ms, matrix 256x256; FOV 30cm, 3mm slice, 30 directions,
ASSET, B = 0,1000]. The original DTI image DICOM files were converted to a FSL recognized
NIfTI file format, using MRIConvert (http://lcni.uoregon.edu/downloads/mriconvert), before
processing in FSL from semi-automated script. In total, 12 DTI parametric maps were calcu-
lated using FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/), including: isotropic (p) and anisotropic
(q) diffusion, mean diffusivity (MD) and fractional anisotrophy (FA) based on previously pub-
lished methods [5].
DSC-pMRI. Prior to DSC acquisition, preload dose (PLD) of 0.1 mmol/kg was adminis-
tered to minimize T1W leakage errors. After PLD, we employed Gradient-echo (GE) EPI [TR/
TE/flip angle = 1500ms/20ms/60°, matrix 128x128, thickness 5mm] for 3 minutes. At 45 sec
after the start of the DSC sequence, we administered another 0.05 mmol/kg i.v. bolus Gd-
DTPA [16,17]. The initial source volume of images from the GE-EPI scan contained negative
contrast enhancement (i.e., susceptibility effects from the PLD administration) and provided
the MRI contrast labeled EPI+C. At approximately 6 minutes after the time of contrast injec-
tion, the T2W signal loss on EPI+C provides information about tissue cell density from con-
trast distribution within the extravascular, extracellular space [18]. We performed leakage
correction and calculated relative cerebral blood (rCBV) based on the entire DSC acquisition
using IB Neuro as referenced [17]. We also normalized rCBV values to contralateral normal
appearing white matter as previous described [16,17].
Image coregistration. For image coregistration, we employed tools from ITK (www.itk.
org) and IB Suite (Imaging Biometrics) as previously described [17]. Because the majority of
MRI contrasts (4 out of 8) originated from the DTI acquisition, we chose to coregister all data-
sets to the relatively high quality DTI B0 anatomical image volume. This offered the additional
advantage of minimizing potential distortion errors (from data resampling) that could prefer-
entially impact the mathematically sensitive DTI metrics. This also avoided upsampling of
advanced MRI maps to the relatively high resolution of T1W stereotactic data (particularly
when acquired with 512x512 matrix), which could result in textural artifacts during image pro-
cessing. Ultimately, the coregistered data used for texture analysis exhibited in plane voxel res-
olution of ~1.2 mm (256x256 matrix) and slice thickness of 3mm.
MRI and Texture Analysis Detect GBM Tumor Extent
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Texture analysis and image processing
A board-certified neuroradiologist (LH) placed square (8x8 voxel) regions of interest (ROIs) at
the locations corresponding to each biopsy site. For all analysis methods, we extracted ROIs
from original images and analyzed each independently. Prior to texture analysis, we acquired
first order statistics from raw image signals: average and standard deviation (SD) of gray-level
intensities. Next, intensity values within each extracted ROI were mapped onto the range
0–255. This step helped standardize intensities between ROIs and reduced effects of intensity
non-uniformity on features extracted during subsequent texture analysis. In this study, we
incorporate 3 separate but complementary texture algorithms with multi-parametric MRI to
characterize GBM’s regional variability in histologic tumor content [11–14]. Multiple texture
algorithms offer similar advantages to using multiple MR contrasts—we expect each algorithm
to provide additional information. We applied each of the three texture analysis methods for
each ROI, which generated a total of 30 texture features for each of 8 total MRI contrasts (T1
+C, T2W, rCBV, EPI+C, p, q, MD, FA). Therefore, at each coregistered ROI, we calculated a
total of 240 texture features, in addition to the 16 raw features (i.e., mean, SD for 8 MRI con-
trasts), yielding a total of 256 image-based features for classification. The 3 texture analysis
methods are described briefly below.
Gray Level Co-Occurrence Matrix (GLCM). GLCM provides detailed gray scale data by
describing the angular relationships and distances between neighboring image voxels with sim-
ilar gray scale intensities [11]. Commonly used in texture analysis, GLCM uses second order
statistics of the distribution of gray-scale intensity level within a ROI. Each element in the co-
occurrence matrix shows how often a pair of intensity levels is seen in a configuration defined
by a certain radius and angle. The co-occurrence matrix was computed by averaging over four
uniformly distributed angular directions (00, 450, 900, and 1350) to produce a set of 13 rotation-
ally invariant features: entropy (matrix randomness), energy/angular second moment (pixel
repetition/orderliness, measures image homogeneity), homogeneity (uniformity of co-occur-
rence matrix), dissimilarity (measurement of how different each matrix element is), and corre-
lation (measurement of gray-tone linear dependencies) [11]. In total, we calculated 13 GLCM
texture features at each ROI for each MRI contrast.
Local Binary Patterns (LBP). LBP provides highly discriminatory rotational and illumi-
nation invariant structural information by labeling each image voxel (in binary fashion) as
higher or lower intensity compared with neighboring voxels [12]. Highly cited as a method for
texture description, LBP evaluates the intensity distribution of the set of points within a certain
radius of each voxel in the ROI. Local binary numbers are categorized into ‘uniform’ and ‘non-
uniform’ patterns based on the number of bit-wise transitions from 0 to 1 or visa versa. A histo-
gram of the labels is used as a measure of uniformity for the ROI. We used the neighborhood
radius of three voxels (the 24 points circularly surrounding each voxel) as the ROI for our
experiments. Given the 8x8 voxel ROI size, the 3-voxel radius represents the maximum for
confining analysis within the ROI while providing larger scale pattern analysis. We chose not
to use a smaller radius (e.g., 1-voxel or 2-voxel) because these provide smaller scale patterns
that are already provided by GLCM. The value of bins in a 12-bin histogram was reported as
the set of feature for this method. In total, we calculated 12 LBP texture features at each ROI
for each MRI contrast.
Discrete Orthonormal Stockwell Transform (DOST). DOST directly measures local spa-
tial frequencies, which have shown specific applicability to neurologic diseases such as glioma
[13,14]. The DOST provides a complete minimal multi-resolution spatial-frequency represen-
tation of an image. It maintains the phase information while avoiding redundant calculations
of time-frequency information and thus being computationally less expensive. The two-
MRI and Texture Analysis Detect GBM Tumor Extent
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dimensional DOST uses a dyadic sampling scheme (orders 0,1,2. . .Log (N)-1) to partition the
2D Fourier transform of the image into non-overlapping sections. Each section, including only
a band-limited subspace of the FT domain, is shifted in frequency and phase to produce the
DOST image. Averaging DOST elements in each section results in a harmonics image from
which we calculated rotationally invariant features [13,14]. In total, we calculated 5 DOST fea-
tures at each ROI for each MRI contrast.
Principal Component Analysis (PCA) for dimension reduction
With a total of 256 image-based features from each ROI and corresponding biopsy sample, the
dimensionality of the image-based features far exceeded the sample size, increasing the risk of
overfitting artifacts and creating challenges for classification. To address this, we used Principal
Component Analysis (PCA) which identifies the linear combination of features, called Princi-
pal Components (PCs), to reduce the dimensionality of the imaging data [19–21]. Here we
identified the PCs separately for each MRI contrast and texture algorithm for better clinical
interpretation. Usually, between 1–3 PCs sufficiently account for the variability in the original
feature space, so we retained those PCs that accounted for 85% of original feature variability
for further analysis [19–21].
Classification with sequential forward feature selection
We used classification algorithms with sequential forward feature selection to identify the sub-
set of image-based PCs (determined from PCA above) with the greatest combined discrimina-
tion for biopsy tumor content (high- vs low-tumor). To represent the spectrum of
classification methodologies, we separately applied 3 distinct but commonly described classifi-
cation algorithms: Diagonal Linear Discriminate Analysis (DLDA), Diagonal Quadratic Dis-
criminate Analysis (DQDA) and Support Vector Machines (SVM) [22–24]. As the names
imply, DLDA identifies linear classification boundaries to separate classes, while DQDA identi-
fies quadratic boundaries. SVM can identify complex boundaries for class separation [22–24].
We determined classification accuracy using leave-one-out cross validation (LOOCV). With
LOOCV, all samples but one are used to develop the classifier (i.e., training set) with one ran-
domly chosen sample serving as the test case for classification performance [13,14]. This pro-
cess repeats for all samples in the dataset (i.e., 60 separate trial runs in our cohort), until each
sample in the cohort has served as the test sample. The averaged accuracy is the overall cross
validation (CV) accuracy. In building the classification model, the PCs are selected using
sequential forward feature selection, which identifies the PC with greatest discriminatory
power (e.g. PC1), then evaluates and adds additional PCs that contribute incremental gains to
classification accuracy [19,20]. The iterative process continues to add remaining PCs to the
classification model until accuracy gains cease (defined as incremental gain of<1%). Of all ML
methods, DLDA identified the highest CV accuracy with the fewest required PCs (S1 Appen-
dix). Thus, we henceforth report the results from the DLDA analysis.
Results
Training and Validation biopsy datasets
In total, we collected 82 biopsy samples from 18 GBM patients. We describe the distribution of
training (60 biopsies, 11 patients) and validation (22 biopsies, 7 patients) biopsy samples
throughout enhancing core (ENH) and BAT in Table 1. The vast majority of biopsies (90%)
were separated by>1cm. Overall, 59.2% of tissue samples from ENH demonstrated high
tumor content, similar to the frequency of adequate tumor samples reported by the TCGA
MRI and Texture Analysis Detect GBM Tumor Extent
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(60.2%). When samples originated from BAT, a much lower percentage (21.2%) of samples
demonstrated high tumor content.
Classification accuracy
Table 2 lists selected features and the cross-validation (CV) accuracy for DLDA, DQDA and
SVM. Specifically, DLDA with sequential forward feature selection, identified 3 MRI-based tex-
ture features that optimized the classification model to distinguish high- vs. low-tumor biopsy
samples (85% accuracy). The three features are: raw measure of rCBV, GLCM feature from
EPI+C and LBP feature from T1+C. In general, rCBV provides non-invasive measures of
microvascular volume, which link closely to histologic tumor content, malignant potential, and
prognosis [7,16,17]. The EPI+C MRI contrast (measured at ~ 5 minutes after contrast injec-
tion) measures negative enhancement (i.e., signal loss) that persists on static T2WGradient
Echo images from Gd-DTPA extravasation and distribution within the extracellular space.
This has been linked closely to tissue cellular density [18]. Finally, T1+C measures Gd-DTPA
contrast enhancement from blood brain barrier (BBB) disruption and represents a secondary
feature of tumor aggression [24].
After completing the MRI feature selection on the training dataset (n = 60), we applied the
optimized model (using all three features) to classify high- vs. low-tumor content biopsies in a
Table 1. Summary of tissue samples and test performance in both training and validation datasets.
Training Set Validation Set
(n = 11 subjects) (n = 7 subjects)
ENH BAT Both ENH BAT Both
Total samples 35 25 60 14 8 22
High tumor samples 22 5 27 7 2 9
(% of total samples) (62.9%) (20%) (45%) (50%) (25%) (41%)
Low tumor samples 13 20 33 7 6 13
(% of total samples) (37.1%) (80%) (55%) (50%) (75%) (59%)
Imaging accuracy(high vs low tumor) 82.9% 88% 85.0% 78.6% 87.5% 81.8%
Sensitivity(identify high-tumor) 86.4% 80% 85.2% 100% 100% 100%
Specificity(identify high tumor) 76.9% 90% 84.8% 57.1% 83.3% 69.2%
PPV(predict high tumor) 86.4% 66.7% 82.1% 70% 66.7% 69.2%
NPV(exclude high tumor) 76.9% 94.7% 87.5% 100% 100% 100%
Distribution of biopsy samples by tumor content (high- vs. low-) for enhancing core (ENH) and non-enhancing BAT in both training and validation datasets.
Test accuracies (sensitivity, specificity) for the optimized model (based on 3 MRI texture features) are shown and include positive and negative predictive
values (PPV, NPV).
doi:10.1371/journal.pone.0141506.t001
Table 2. Summary of selected MRI-based texture features to optimize CV training accuracy.
MRI-based feature Texture algorithm Texture description MRI Contrast Physiologic correlate
rCBV(raw mean) – – Relative cerebral blood volume (rCBV) Micro-vessel volume
EPI+C-GLCM Gray level co-occurrence matrix (GLCM) Gray scale intensities T2*W negative enhancement (EPI+C) Tumor cell density
T1+C-LBP Local binary product (LBP) Structural uniformity T1W contrast enhancement (T1+C) BBB disruption
Machine learning (ML) selected the 3 MRI-based texture features that optimized cross validation (CV) accuracy based on leave-one-out cross validation
(LOOCV) of the training set data (60 biopsies, 11 patients). The overall CV accuracy based on the 3 features is 85%.
doi:10.1371/journal.pone.0141506.t002
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separate, retrospectively collected validation set (22 biopsies, 7 patients). The CV accuracy of
the training set and the accuracy of applying the training model on the separate validation set
are listed in Table 1 for both enhancing core (ENH) and BAT. In the validation set, model clas-
sification achieved an overall accuracy (81.8%) similar to that in the training dataset. Impor-
tantly, the model achieved a high degree of accuracy in non-enhancing BAT (88% training,
87.5% validation), which represents a problematic area for conventional CE-MRI-guided biop-
sies [3,5,7,25]. Specifically, tumor-rich populations show low prevalence in the BAT (21.2% for
all biopsies in our study) and typically remain indistinguishable from non-tumoral edema on
CE-MRI [5]. The positive predictive values (PPV) of 66.7% in both training and validation sets
suggests that using the MRI texture model would significantly improve the localization and
recovery of tumor-rich BAT targets compared to current CE-MRI guided biopsy methods, as
shown in Fig 1. Ten percent of training set biopsies (n = 6) were located within 5-10mm of
adjacent biopsies. To test the potential confounding effects on accuracy, we performed a suba-
nalysis that excluded these samples, as shown in S2 Appendix. With 54 total samples, the
model achieved an accuracy of 85.2%, nearly identical to the main analysis, suggesting that the
effects are negligible.
Fig 1. ML-based MRI invasionmaps show tumor-rich (>80% tumor nuclei) extent throughout ENH and BAT. (A,B,C,E) Biopsy locations within the
non-enhancing BAT zone (green dots, arrows) on T1+C (A,D) and T2W (B,E) images correspond with high-tumor (>80% tumor nuclei) and low-tumor (<80%
tumor nuclei) tissue samples on histologic analysis. (C,F) Color overlay maps with manual tracings (green) around BAT show the probability (range 0–1) of
tumor-rich (red) vs tumor-poor (green/blue) content, based on ML analysis and multi-parametric MRI in 60 training biopsies and 22 validation biopsies. The
maps show correspondence between tumor-rich (B, red) and tumor-poor (D, blue/gray) biopsy samples.
doi:10.1371/journal.pone.0141506.g001
MRI and Texture Analysis Detect GBM Tumor Extent
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Discussion
Genetic profiling represents the future of neuro-oncology but hinges on the recovery of ade-
quate biopsy material from representative tumor segments [4,6]. While contrast-enhanced
MRI (CE-MRI) serves as the current standard for image-guided surgery, distinct limitations
exist. For instance, neurosurgeons routinely target CE-MRI enhancing core (ENH) for its pre-
sumed tumor-rich composition, but this yields adequate tumor in only ~60% of the cases from
TCGA and our cohort [4]. Further, the BAT harbors residual populations that are most impor-
tant to characterize because they universally recur, but the low prevalence of tumor-rich foci
(~20% in our cohort) and the lack of enhancement in BAT limit the success of CE-MRI-guided
biopsies [5,25]. In this study, we improve the detection of tumor-rich targets throughout ENH
and BAT by combining CE-MRI with advanced imaging and texture analysis. Advanced MRI
metrics on diffusion tensor imaging (DTI), diffusion weighted imaging (DWI), and perfusion
MRI (pMRI) correlate with hallmark features of tumor aggression, such as white matter inva-
sion (DTI), cellular proliferation (DWI), and tumoral angiogenesis (pMRI) [5,7–10]. Mean-
while, MRI texture–which characterizes regional heterogeneity and microstructure–can
capture additional tissue features such as molecular status (i.e., MGMT, 1p/19q) and histologic
identity [11–14,24].
Previous glioma studies have used advanced MRI-guided stereotactic biopsies to validate
the correlations with spatially matched regional histology. Barajas et al. compared DWI and
pMRI measurements with tumor cell density, among other histologic indices (e.g., microvascu-
lar hyperplasia, cell proliferation), in ENH and BAT biopsies [7]. Compared with DWI, they
found that tumor cell density correlated more strongly with pMRI metrics, namely rCBV and
relative peak height (rPH) in ENH samples, and rPH in BAT samples. Ellingson et al. deter-
mined the correlations between apparent diffusion coefficient (ADC, closely related to MD) on
DWI and tumor cell density [8]. Similarly, LaViolette et al. confirmed the utility of ADC to
identify regions of hypercellular non-enhancing tumor in ex-vivo cases, while Stadlbauer
found FA to be more informative than MD (closely linked to ADC) [9,10]. Finally, Price et al.
determined DTI thresholds for isotropic (p) and anisotropic (q) diffusion to distinguish nor-
mal white matter from tumoral infiltration and gross replacement [5]. While these studies have
helped to establish advanced MRI-based correlates in glioma, none have tested the accuracy to
classify biopsy targets based on quantitative thresholds for histologic tumor content (e.g.,
80% vs<80% tumor nuclei). Further, we don’t yet know the diagnostic value of combining
multiple complementary metrics or extracting regional image texture patterns from advanced
MRI maps.
Based on the correlations in our training set, we have used machine learning (ML) to iden-
tify three MRI-based features that optimize classification accuracy for high- vs. low-tumor con-
tent (Table 2). Mean rCBV contributes the most to model accuracy, which aligns with previous
pMRI studies showing strong correlations between rCBV and histologic tumor content,
tumoral proliferation, and malignant potential. In particular, densely cellular tumor elaborates
large microvascular networks (to support metabolic demands), which correspond to elevated
rCBV values on pMRI [7,16,17]. Signal loss on T2WEPI+C relates to contrast agent extrava-
sation and subsequent equilibration within the extracellular space. Clinical and preclinical
studies have shown how these susceptibility effects correlate strongly with tumor cell density
and size, similar to using MD, ADC, and isotropic diffusion (p) on DWI and DTI [5,7,8–10].
Meanwhile, signal changes on T1+C represent regional differences in contrast extravasation
(and signal rise) due to blood brain barrier (BBB) disruption. While T1+C routinely guides
CE-MRI biopsies, our model shows that structural uniformity textures, rather than simply the
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presence/absence of T1+C enhancement, provide the greater contribution to test accuracy
[12,24].
Overall model accuracy (85% training, 81.8% validation) suggests that the ML-based MRI
texture model can guide surgical biopsies to improve recovery of tumor-rich biospecimens
compared to current CE-MRI methods. Particularly encouraging is the high model accuracy
for non-enhancing BAT (88% training, 87.5% validation). Even in the subgroup analysis,
which excludes 6 samples within 5–10 mm of each other, the ML-based model achieves high
accuracy in BAT (90.5%). Based on current limitations of CE-MRI and low prevalence of
tumor-rich foci in BAT (21% in full cohort, 13.7% in subgroup analysis), neurosurgeons would
need approximately 5–7 biopsy attempts to recover one adequate tumor-rich sample (80%
tumor nuclei) [5,25]. The ML-based model’s PPV of ~67% significantly improves the efficiency
of tumor-rich recovery in the problematic non-enhancing BAT zone, as illustrated in Fig 2.
Also, the NPV (94.7% training, 100% validation) of the ML model would suggest a high degree
of confidence in excluding tumor-rich populations in tumoral subregions, thereby improving
surgical safety by preventing unnecessary biopsies. Besides biopsy guidance, the ML-based
MRI texture model also presents applicability for improving the extent of maximal surgical
resection, which correlates strongly with patient survival [26]. Currently, CE-MRI guides gross
total resection (GTR) based on enhancing core (ENH), but this can leave substantial residual
Fig 2. ML-basedmodel improves tumor-rich biopsy delineation compared with CE-MRI. (A) ML-based MRI texture model in the full dataset (n = 82,
Table 1) shows higher positive predictive values (PPV) (66.7% in BAT, 81.3% in ENH) for recovering tumor-rich samples compared with CE-MRI (21.2% in
BAT, 59.2% in ENH). These PPVs suggest that the ML-based model would help recover tumor-rich BAT samples with over three times greater efficiency
compared with CE-MRI guidance. (B) ML-based MRI texture model in the subanalysis (n = 76, S2 Appendix) provides higher positive predictive values (PPV)
(57.1% in BAT, 80.6% in ENH) for recovering tumor-rich samples (>80% tumor nuclei) compared with CE-MRI (13.8% in BAT, 59.6% in ENH). Based on
these PPVs, the ML-based model would enable four times more efficient tumor-rich recovery from BAT compared with CE-MRI guidance.
doi:10.1371/journal.pone.0141506.g002
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tumor burden in the non-enhancing BAT. Using the ML-based model to map tumor infiltra-
tion in BAT could help surgeons plan safer and more extensive resections to improve local con-
trol and patient outcomes. The study results here should provide the impetus and justification
for future clinical trials that integrate this ML-based model into neuronavigational platforms to
prospectively validate test accuracy and potential clinical impact.
A number of studies have shown the utility of intraoperative fluorescence microscopy
with 5-aminolevulinic acid (5-ALA) to facilitate gross total resection (GTR) of enhancing
core (ENH), which currently represents the primary target of surgical biopsy and resection
[27,28]. The ENH tumor segment is well visualized on CE-MRI because of gadolinium-
based contrast agent (GBCA) extravasation through a disrupted blood brain barrier (BBB).
This BBB dependence also accounts for 5-ALA visualization of the ENH tumor segment,
which may explain why both CE-MRI and 5-ALA poorly characterize the non-enhancing
invasive tumor in BAT (which maintains BBB integrity) [27,28]. In fact, 5-ALA shows poor
sensitivity for detection of invasive non-enhanicng tumor in BAT, with negative predictive
value (NPV) as low as 26% [27]. For these reasons, the invasive tumor segment in BAT typi-
cally remains unresected, unbiopsied, and uncharacterized despite the use of CE-MRI and/
or 5-ALA guidance. Neglecting BAT tumor at the time of surgery can leave substantial
unresected tumor burden that contributes to recurrent disease. This could also have partic-
ular impact on the selection of adjuvant targeted therapies in the future, as we move
towards the paradigm of individualized oncology, because the invasive tumor segment rep-
resents the focus of adjuvant therapy but can harbor different therapeutic targets than those
detected in ENH biopsies [6,7,25]. Unless these BAT targets are biopsied and characterized,
sampling error could misinform treatment, potentiating recurrence of pre-existing resistant
clones. The ML-based model presented here helps to address this gap, by significantly
improving the detection and recovery of tumor-rich biopsies in the problematic non-
enhancing BAT zone (Fig 2).
In this study, we define high tumor content (80% tumor) based on published TCGA cri-
teria for sample adequacy [4]. This threshold helps to maximize tumoral DNA quality by
minimizing non-tumoral contamination. While our ML model demonstrates high accuracy
to distinguish tumor content based on this specific histologic threshold, classification of sam-
ples based on other thresholds (e.g., 20%, 50%, 75% tumor nuclei) would require re-training
of the ML model to maximize diagnostic accuracy. In other words, an ML model for one his-
tologic threshold may not optimally translate to other histologic thresholds. This represents
one of the limitations to using ML methodology. Nonetheless, additional ML models can be
developed in future work for other clinically relevant histologic thresholds, or potentially for
prediction of tumor cell density as a continuous variable (i.e., tumor nuclei range from
0–100%). We must also note that different histologic thresholds may favor specific MRI-
based phenotypes. For instance, high tumor density may select for “proliferative” imaging
phenotypes, while lower tumor thresholds (i.e., 50% or20% tumor fraction) may associ-
ate with “invasive” phenotypes in which tumor admixes more evenly with surrounding non-
tumoral parenchyma [5]. Thus, while DWI and DTI metrics were not selected in this study,
they may prove useful when evaluating other tumor thresholds. Such thresholds may have
greater applicability for image-guided interventions such as radiation therapy (RT), which
generally targets both densely cellular tumor and more diffusely infiltrative tumor-poor
regions [29].
We used Principal Component Analysis (PCA) to help interpret the high dimensional data
that results from combining multiple texture algorithms and complementary MRI contrasts.
Specifically, PCA identifies linear combinations of features, called Principal Components
(PCs) that account for most variability across the original features [19–21]. This eliminates
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>90% of the original features and distills the imaging data to only a few representative PCs for
each MRI contrast. This aligns the dimensionality of imaging data with our study’s sample size.
Also, we employed three different classification algorithms (DLDA, DQDA, SVM) to help rep-
resent a broader spectrum of methodologies that might impact the development and training
of our classification model. Of the three algorithms, we found that DLDA provided the greatest
test accuracy with the fewest required PCs to build the predictive model.
We recognize potential limitations. First, while this study demonstrates proof of concept
that multi-parametric MRI and texture analysis can facilitate tumor localization, we recog-
nize the need to validate these findings in a larger patient population. Second, we classify the
adequacy of tumor content based on well-established guidelines, which ensure the quality of
DNA isolation and the integrity of genetic analysis. Nonetheless, the requirements for tumor
content may change as genetic sequencing technology improves, and future studies may
prove necessary to evaluate the accuracy of MRI texture based on other histologic criteria
and/or tumor thresholds. Third, image distortions and brain shift following craniotomy
could also lead to misregistration errors. To compensate, neurosurgeons used small craniot-
omy sizes to minimize brain shift and also visually validated stereotactic image location with
intracranial neuroanatomic landmarks to help correct for random brain shifts. Rigid-body
coregistration of stereotactic and DSC-MR imaging also helped reduce possible geometric
distortions [7,16,17]. Overall, our experience suggests combined misregistration at approxi-
mately 1–2 mm from both brain shift and registration technique, which is similar to that
from previous studies by using stereotactic needle biopsy. Fourth, for each patient, we col-
lected multiple tissue samples from spatially distinct subregions within the same tumor. The
vast majority of biopsy targets were separated by >1 cm. While ~10% of samples were sepa-
rated by 5–10 mm, small ROI sizes minimized the effects of potential sample overlap. None-
theless, we performed a subanalysis that excluded these minority samples, which
demonstrated comparable accuracies to the main study, suggesting negligible impact. A final
potential limitation of our study is that the use of multiple biopsies per patient may result in
biased estimates, such as an underestimation of the variance of parameter estimates. In previ-
ous studies, the impact of using multiple biopsies from the same subject did not impact
assessment of the relationship between rCBV and other imaging parameters [16,30]. To
address this in the current study, supplemental analysis (S2 Appendix) excluded biopsies
located within 5-10mm of adjacent biopsies and results remained consistent suggesting a
negligible impact of this limitation.
Supporting Information
S1 Appendix. Summary of classification accuracies. Shown are classification accuracies and
selected MRI features based on DLDA, DQDA, and SVM classification methods. Incremental
accuracy gains are listed for each MRI feature and for each classification method.
(DOCX)
S2 Appendix. Summary of tissue samples and test performance from subgroup analysis in
training and validation datasets. After excluding 6 biopsy samples (within 5–10 mm of each
other) from the training dataset, the table shows the distribution of biopsy samples by tumor
content (high- vs. low-) for enhancing core (ENH) and non-enhancing BAT in both training
(n = 54) and validation (n = 22) datasets. Test accuracies (sensitivity, specificity) for the opti-
mized model (using the 3 MRI-based features in Table 2) are shown and include positive and
negative predictive values (PPV, NPV).
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